Disease · HP_0001943

Hypoglycemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Hypoglycemia. Diseases, record HP_0001943. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001943

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Hypoglycemia; Open Targets
Open Targets ID: HP_0001943; Open Targets
Other names: Hypoglycaemia, Low blood sugar; Open Targets
Disease Ontology: DOID:9993; Disease Ontology
NCI Thesaurus: C3126; NCI Thesaurus
Highest stage of its drugs: Approval, for 5 of its 68 drugs, from ATC, DailyMed, FDA, PMDA and TTD; Open Targets

Drugs68

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
GLUCAGON	CHEMBL5314341	Protein	Approval	DailyMed, PMDA and TTD	36	28	28	Drugs and targets
DASIGLUCAGON	CHEMBL4297741		Approval	TTD	10	9	9	Drugs and targets
DIAZOXIDE	CHEMBL181	Small molecule	Approval	ATC	3	2	2	Drugs and targets
DASIGLUCAGON HYDROCHLORIDE	CHEMBL4650274	Protein	Approval	FDA	1	0	0	Drugs and targets
DONISLECEL	CHEMBL4594332	Cell	Approval	FDA	1	0	0	Drugs and targets
INSULIN LISPRO	CHEMBL1201538	Protein	Phase 3	ClinicalTrials.gov	4	4	3	Drugs and targets
ERSODETUG	CHEMBL5314739	Antibody	Phase 3	ClinicalTrials.gov	6	3	3	Drugs and targets
EMPAGLIFLOZIN	CHEMBL2107830	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
INSULIN DEGLUDEC	CHEMBL2107869	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
INSULIN GLARGINE	CHEMBL1201497	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 68

See all 68 drugs

Targets73

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
INSR	Insulin receptor	7	Insulin receptor agonist	Phase 3	https://conductscience.org/library/genes/3643	Drugs and targets
GCGR	Glucagon receptor	5	Glucagon receptor agonist; Glucagon receptor inhibitor	Approval	https://conductscience.org/library/genes/2642	Drugs and targets
GLP1R	Glucagon-like peptide 1 receptor	5	Glucagon-like peptide 1 receptor agonist; Glucagon-like peptide 1 receptor antagonist	Phase 3	https://conductscience.org/library/genes/2740	Drugs and targets
ADRB2	Adrenergic receptor beta	3	Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor agonist; Beta-2 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/154	Drugs and targets
EPOR	Erythropoietin receptor	3	Erythropoietin receptor agonist	Unknown	https://conductscience.org/library/genes/2057	Drugs and targets
SSTR1	Somatostatin receptor	3	Somatostatin receptor 1 agonist; Somatostatin receptor agonist	Phase 3	https://conductscience.org/library/genes/6751	Drugs and targets
SSTR2	Somatostatin receptor	3	Somatostatin receptor 2 agonist; Somatostatin receptor agonist	Phase 3	https://conductscience.org/library/genes/6752	Drugs and targets
SSTR3	Somatostatin receptor	3	Somatostatin receptor 3 agonist; Somatostatin receptor agonist	Phase 3	https://conductscience.org/library/genes/6753	Drugs and targets
SSTR5	Somatostatin receptor	3	Somatostatin receptor 5 agonist; Somatostatin receptor agonist	Phase 3	https://conductscience.org/library/genes/6755	Drugs and targets
ADRA1A	Adrenergic receptor alpha	2	Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 antagonist	Phase 2	https://conductscience.org/library/genes/148	Drugs and targets

1 to 10 of 73

See all 73 targets

Trials101

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01468987	A Study in Participants With Type 2 Diabetes Mellitus	Phase 3	1,369	2018-04-17	Diabetes Mellitus, Type 2	INSULIN LISPRO, INSULIN PEGLISPRO	Its record names the disease	ClinicalTrials.gov
NCT01340768	Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)	Phase 3	870	2012-10-08	Type 2 Diabetes Mellitus	SITAGLIPTIN	Its record names the disease	ClinicalTrials.gov
NCT02735044	Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus	Phase 3	463	2019-06-19	Type 1 Diabetes Mellitus	INSULIN GLARGINE	Its record names the disease	ClinicalTrials.gov
NCT01798706	Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients	Phase 3	350	2016-10-14	Type 2 Diabetes	LIXISENATIDE	Its record names the disease	ClinicalTrials.gov
NCT03378635	A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects	Phase 3	170	2021-05-10	Hypoglycemia, Diabetes Mellitus, Type 1	DASIGLUCAGON, GLUCAGON	Its record names the disease	ClinicalTrials.gov
NCT03738865	G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes	Phase 3	132	2020-05-13	Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia	GLUCAGON	Its record names the disease	ClinicalTrials.gov
NCT02171130	Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia	Phase 3	129	2019-10-15	Hypoglycemia, Diabetes Mellitus, Drug-Specific Antibodies	GLUCAGON	Its record names the disease	ClinicalTrials.gov
NCT04432090	GPR119 Agonist for Hypoglycemia in Type 1 Diabetes	Phase 2	110	2024-10-17	Diabetes Mellitus, Type 1	MBX-2982	Its record names the disease	ClinicalTrials.gov
NCT02214160	Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies	Phase 2	94	2021-12-08	Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency, Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency, Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency, Trifunctional Protein (TFP) Deficiency, Carnitine-acylcarnitine Translocase (CACT) Deficiency	TRIHEPTANOIN	Its record names the disease	ClinicalTrials.gov
NCT03439072	G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes	Phase 3	81	2019-05-30	Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia	GLUCAGON	Its record names the disease	ClinicalTrials.gov

1 to 10 of 101

See all 101 trials

Comparisons in its trials60

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
LY2605541 + Insulin Lispro vs Insulin Glargine + Insulin Lispro: serious adverse events	79 of 691	63 of 677	1,368	NCT01468987	Trial comparisons
LY2605541 + Insulin Lispro vs Insulin Glargine + Insulin Lispro: Number of Participants With Change in Anti-LY2605541 Antibodies From Baseline to 26 Weeks	152 of 682	161 of 672	1,354	NCT01468987	Trial comparisons
Sitagliptin vs Sulfonylurea Therapy: serious adverse events	1 of 421	0 of 427	848	NCT01340768	Trial comparisons
HOE901-U300 vs Lantus: deaths from any cause	1 of 233	0 of 228	461	NCT02735044	Trial comparisons
HOE901-U300 vs Lantus: serious adverse events	35 of 233	31 of 228	461	NCT02735044	Trial comparisons
Lixisenatide vs Placebo: serious adverse events	8 of 176	10 of 174	350	NCT01798706	Trial comparisons
G-Pen vs Novo Glucagon: Plasma Glucose Response 2	127 of 128	123 of 123	251	NCT03738865	Trial comparisons
G-Pen vs Novo Glucagon: Plasma Glucose Response 1	127 of 128	123 of 123	251	NCT03738865	Trial comparisons
G-Pen vs Novo Glucagon: Severe Hypoglycemia Rescue	127 of 128	123 of 123	251	NCT03738865	Trial comparisons
G-Pen vs Novo Glucagon: deaths from any cause	0 of 127	0 of 123	250	NCT03738865	Trial comparisons

1 to 10 of 60

See all 60 comparisons in its trials

Papers from its trials67

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37166980	RESULT	1	PubMed
34590159	RESULT	1	PubMed
34447992	RESULT	1	PubMed
33616643	RESULT	1	PubMed
32865377	RESULT	1	PubMed
32250530	RESULT	1	PubMed
31535829	RESULT	1	PubMed
29893488	RESULT	1	PubMed
29485006	RESULT	1	PubMed
28188240	RESULT	1	PubMed

1 to 10 of 67

See all 67 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0001943

GET https://conductscience.org/api/diseases/v1/HP_0001943/drugs?page=2

API reference For AI assistants